You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Dermatology
On demand events

EADV 2023 Symposium: Exploring Prurigo Nodularis: From Definition to Pathology and Patient Management

Drs. Chih-Ho Hong, Sarina Elmariah and Brian Kim, and Prof. Sonja Ständer explored prurigo nodularis from definition to pathology and patient management.

Chih-Ho Hong
Sarina Elmariah
Brian Kim
MD
Chih-Ho Hong +3 more

On demand materials

Exploring Prurigo Nodularis: From Definition to Pathology and Patient Management
Dermatology
expert video

Exploring Prurigo Nodularis: From Definition to Pathology and Patient Management

How Should We Define and Classify Prurigo Nodularis?
Dermatology
expert video

How Should We Define and Classify Prurigo Nodularis?

What Drives PN Disease? Exploring the Complexity of PN Pathophysiology
Dermatology
expert video

What Drives PN Disease? Exploring the Complexity of PN Pathophysiology

Can Emerging Treatments Help Address Individual PN Patient Burden?
Dermatology
expert video

Can Emerging Treatments Help Address Individual PN Patient Burden?

PN is Considered a Unique Clinical Entity Distinct from Other Pruritic Diseases and Psychiatric Conditions
Dermatology
expert video

PN is Considered a Unique Clinical Entity Distinct from Other Pruritic Diseases and Psychiatric Conditions

Differences in Manifestations of Type 2 Inflammatory Diseases
Dermatology
expert video

Differences in Manifestations of Type 2 Inflammatory Diseases

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management
Dermatology
Infographic

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management

Learning objectives

  • Recognize and elaborate on prurigo nodularis (PN) disease burden and classification
  • Describe the role of the molecules and processes that drive the complexities of PN disease
  • Review if emerging therapies can help address the heterogeneity of disease burden seen in PN patients

Description

Watch the ADVENT symposium ‘Exploring Prurigo Nodularis: From Definition to Pathology and Patient Management’ presented at EADV 2023, where Dr Hong hosts discussions by Dr Kim, Dr Elmariah and Dr Ständer on many aspects of prurigo nodularis, including the way emerging treatments may help alleviate the burden of chronic diseases on patients.

Tags
symptomsquality of lifesymposium
MAT-GLB-2305481 V2 11/2023

About these experts

Dermatology
MD

Chih-Ho Hong

Clinical Associate Professor in the Department of Dermatology and Skin Sciences, St. Paul’s Hospital, Vancouver, Canada

Dermatology
MD, PhD

Sarina Elmariah

Associate Professor and Dermatology Director at the UCSF Centre for Itch and Neurosensory Disorders at the University of California in San Francisco, California, US

Dermatology
MD

Brian Kim

Professor, Vice Chair of Research, and Site Chair of Mount Sinai West, Icahn School of Medicine, NY, US

Dermatology
MD

Sonja Ständer

Professor of Dermatology and Neurodermatology at the University of Münster; Head of the Interdisciplinary Center for Chronic Pruritus (KCP) at the University Hospital Münster, Germany

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi | Regeneron Logo

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region